Answers are grounded in this paper and cite their sources.
Despite the substantial scale-up in treatment coverage and viral load monitoring, virologic non-suppression persists among people living with HIV in Kenya. In this study, we describe the extent of virologic non-suppression and identify associated factors in people living with HIV under combination antiretroviral therapy and routine viral load monitoring in Kenya. We conducted a retrospective cross-sectional study on routinely collected viral load data generated from January 2016 to June 2025. Mean, median, and proportions were used to describe the variables, and logistic regression analysis was performed to determine the factors associated with virologic non-suppression. The overall virologic non-suppression rate was 7.1%. Increased odds of virologic non-suppression were associated with male sex (adjusted odds ratio [aOR] = 1.35, 95% confidence interval [CI]: 1.33–1.37, P < .001), children (aOR = 2.19, 95% CI: 2.14–2.24, P < .001), adolescents (aOR = 1.77, 95% CI: 1.73–1.81, P < .001), Protease inhibitor based regimen (aOR = 1.12, 95% CI: 1.10–1.15, P < .001), and persistent low-level viremia (aOR = 1.46, 95% CI: 1.24–1.70, P < .001). Longer duration on treatment (73+: aOR = 0.95, 95% CI: 0.93–0.97, P < .001) and Integrase inhibitor-based regimen (aOR = 0.29, 95% CI: 0.28–0.29, P < .001) were protective of non-suppression. Virologic non-suppression was common in the study population. Sex, age, duration on treatment, regimen class, and geographical location were significantly associated with non-suppression. Each of these variables presents opportunities for interventions to help achieve the UNAIDS 95-95-95 goals.
No takes yet. Share an insight, caveat, or question.
Kibui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: